[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619316":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":36,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Antonin HUGEROT, MD","CONTACT","33 3 88 12 79 24","antonin.hugerot@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Médecine intensive - Réanimation - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France",{"type":22,"coordinates":23},"Point",[24,25],7.74553,48.58392,{"lat":25,"lon":24},[28,29,31,34],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":30,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":32,"role":33,"phone":7,"phoneExt":7,"email":7},"Antoine CHANZY, MD","SUB_INVESTIGATOR",{"name":35,"role":33,"phone":7,"phoneExt":7,"email":7},"Vincent CASTELAIN, MD, PhD",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619316",false,"NCT07343037","Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care","Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care: Relevance of the Hscore and Search for the Best Diagnostic Markers","SAMICU","Inclusion Criteria:\n\n* Adult patient (≥18 years old)\n* Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024\n* At least 3 biological signs of HLH:\n\n  * ferritin \\> 2000 ng\u002FmL\n  * triglycerides \\> 1.5 g\u002FL\n  * at least one cytopenia (leukocytes ≤ 5000 G\u002FL, platelets ≤ 110 G\u002FL, hemoglobin ≤ 9.2 g\u002FdL).\n\nExclusion Criteria:\n\nRefusal to participate in the study","ALL","18 Years",{"count":48,"type":49},100,"ESTIMATED","OBSERVATIONAL","Patients with hepatocellular insufficiency and\u002For cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings.\n\nIn international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction.\n\nThe aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.",[53,54],"Hepatic Insufficiency","Cirrhosis, Liver",[53,54,56,57,58,59,60],"Lymphohistiocytic hemophagocytosis","Hepatocellular insufficiency","Invasive aspergillosis","Azole antifungals","Liver dysfunction.","2026-01-06",{"date":63,"type":64},"2026-01-15","ACTUAL",{"date":66,"type":64},"2025-08-29",{"date":68,"type":49},"2026-08-29",{"name":5,"class":6},1]